Study of BT02 for blood cancers that returned or didn't respond
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called BT02 for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or stopped responding to treatment. The goal is to see if BT02 can help when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 69 years old.
- You have a confirmed blood cancer (leukemia, lymphoma, or multiple myeloma) that has come back or is not responding to treatment.
- If you have leukemia, a bone marrow test shows at least 5% blast cells (immature cells).
- You are able to do daily activities on your own (ECOG score 0 or 1).
- Your organs (like liver, kidneys, and bone marrow) are working well enough.
- You agree to use effective contraception during the study if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug called BT02 for people with advanced lung cancer who have already tried other treatments. It aims to see if BT02 is safe and effective for non-small cell or small cell lung cancer.
This trial tests a new drug called BT02 for people with advanced melanoma that has not responded to prior treatments. The drug is designed to help your immune system fight the cancer.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.